Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

L.H. van der Helm, N.J.G.M. Veeger, M. van Marwijk Kooy, A. Beeker, O. de Weerdt, M. de Groot, C. Alhan, M. Hoogendoorn, L. Laterveer, A.A. van de Loosdrecht, J. Koedam, E. Vellenga, G. Huls

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)877-882
JournalLeukemia research
Issue number8
Publication statusPublished - 2013

Cite this